[Serotonin and pulmonary arterial hypertension]

Area of Science:

• Cardiovascular Research
• Molecular Medicine
• Pulmonary Hypertension Research

Context:

• Pulmonary arterial hypertension (PAH) involves pulmonary vascular remodeling driven by pulmonary artery smooth muscle cell (PA-SMC) proliferation.
• Increased serotonin transporter (5-HTT) expression in PA-SMCs mediates serotonin-induced proliferation, contributing to PAH.
• Genetic factors, including 5-HTT gene polymorphism, influence PAH severity, particularly in COPD-related cases.

Purpose:

• To investigate the role of serotonin transporter (5-HTT) in the pathophysiology of pulmonary arterial hypertension (PAH).
• To evaluate the therapeutic potential of 5-HTT inhibitors in experimental and human PAH.
• To explore the relationship between 5-HTT overexpression, PA-SMC proliferation, and PAH development.

Summary:

• Overexpression of the serotonin transporter (5-HTT) in pulmonary artery smooth muscle cells (PA-SMCs) drives proliferation and contributes to pulmonary arterial hypertension (PAH).
• Selective 5-HTT inhibitors have demonstrated efficacy in preventing and reversing experimental PAH models.
• Genetic variations in the 5-HTT gene may correlate with PAH severity, suggesting a personalized medicine approach.

Impact:

• 5-HTT inhibitors represent a promising therapeutic strategy for human PAH, with ongoing clinical trials.
• Further research into 5-HTT mechanisms and interactions with genes like BMPR2 will deepen the understanding of PAH pathophysiology.
• This research opens avenues for novel drug development targeting molecular pathways in PAH.